# SLXN (Silexion Therapeutics Corp.) - SEC EDGAR Financial Statements

> Silexion Therapeutics Corp. reported $6.83M in total assets and a net loss of $13.23M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/SLXN
- Markdown: https://convexityos.com/fundamentals/SLXN.md
- SEC CIK: 0002022416
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:16 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002022416&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$13.52M | Operating profit |
| Net Income | FY 2025 | -$13.23M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$71.54 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$11.74M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $4.76M | Total debt: $374K |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Research & Development | $7.14M | $5.82M | $3.71M |
| Total Operating Expenses | $11.63M | $12.57M | $4.68M |
| **Operating Income** | -$11.63M | -$12.57M | -$4.68M |
| **EBITDA** | -$11.62M | -$12.55M | -$4.64M |
| Interest Income | $155K | $28K | $153K |
| Income Before Tax | -$11.91M | -$16.51M | -$5.08M |
| Income Tax Expense | $3.0K | $10K | $32K |
| **Net Income** | -$11.91M | -$16.52M | -$5.11M |
| Basic EPS | $21,333.33 | $940,333.33 | $7,187,382,187.38 |
| **Diluted EPS** | $21,333.33 | $940,333.33 | $7,187,382,187.38 |
| Basic Shares Outstanding | 558 | 17 | 0 |
| Diluted Shares Outstanding | 558 | 17 | 0 |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $1.29M | $2.21M | $1.37M | $3.38M | $2.16M | $1.02M | $590K | $871K |
| Total Operating Expenses | $2.68M | $3.68M | $2.75M | $4.41M | $3.29M | $2.28M | $1.65M | $1.90M |
| **Operating Income** | -$2.68M | -$3.68M | -$2.75M | -$4.41M | -$3.29M | -$2.28M | -$1.65M | -$1.90M |
| **EBITDA** | -$2.68M | -$3.68M | -$2.75M | -$4.40M | -$3.29M | -$2.28M | -$1.65M | -$1.91M |
| Interest Income | $18K | $14K | $32K | $69K | $39K | $44K | $2.0K | $3.0K |
| Income Before Tax | -$2.53M | -$3.55M | -$2.73M | -$4.41M | -$3.26M | -$2.50M | -$1.74M | -$1.75M |
| Income Tax Expense | -- | -- | -- | -- | $0 | $3.0K | -- | $1.0K |
| **Net Income** | -$2.53M | -$3.55M | -$2.73M | -$4.41M | -$3.26M | -$2.50M | -$1.74M | -$1.75M |
| Basic EPS | $13.70 | $1,230.95 | $2,023.81 | -- | $691.14 | $10,283.33 | $9,142.86 | -- |
| **Diluted EPS** | $13.70 | $1,230.95 | $2,023.81 | -- | $691.14 | $10,283.33 | $9,142.86 | -- |
| Basic Shares Outstanding | 184.9K | 2.9K | 1.4K | -- | 4.7K | 243 | 190 | -- |
| Diluted Shares Outstanding | 184.9K | 2.9K | 1.4K | -- | 4.7K | 243 | 190 | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Cash & Cash Equivalents | $5.99M | $1.19M | $4.59M |
| **Cash & Short-Term Investments** | $5.99M | $1.19M | $4.59M |
| Other Current Assets | $49K | $62K | $24K |
| **Total Current Assets** | $6.64M | $2.25M | $4.98M |
| Property, Plant & Equipment, Net | $25K | $30K | $49K |
| **Total Non-Current Assets** | $578K | $613K | $277K |
| **Total Assets** | $7.21M | $2.86M | $5.26M |
| Accounts Payable | $787K | $929K | $319K |
| Other Current Liabilities | -- | $0 | $200K |
| **Total Current Liabilities** | $2.76M | $3.52M | $2.20M |
| **Total Non-Current Liabilities** | $1.85M | $3.33M | $59K |
| **Total Liabilities** | $4.61M | $6.85M | $2.25M |
| **Total Debt (incl. Leases)** | $468K | $526K | $171K |
| Common Stock | $42K | $2.0K | $1.0K |
| Retained Earnings | -$55.17M | -$43.25M | -$26.81M |
| **Total Stockholders' Equity** | $2.60M | -$3.99M | -$15.48M |
| Total Equity | $2.60M | -$3.99M | $3.00M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $4.76M | $2.23M | $2.41M | $5.99M | $9.24M | $3.47M | $6.15M | $1.19M |
| **Cash & Short-Term Investments** | $4.76M | $2.23M | $2.41M | $5.99M | $9.24M | $3.47M | $6.15M | $1.19M |
| Other Current Assets | $102K | $111K | $96K | $49K | $47K | $63K | $58K | $62K |
| **Total Current Assets** | $6.11M | $3.74M | $4.07M | $6.64M | $11.05M | $5.24M | $7.72M | $2.25M |
| Property, Plant & Equipment, Net | $21K | $20K | $23K | $25K | $26K | $30K | $32K | $30K |
| **Total Non-Current Assets** | $716K | $505K | $537K | $578K | $559K | $560K | $586K | $613K |
| **Total Assets** | $6.83M | $4.25M | $4.60M | $7.21M | $11.61M | $5.80M | $8.31M | $2.86M |
| Accounts Payable | $1.24M | $1.18M | $912K | $787K | $946K | $692K | $722K | $929K |
| Other Current Liabilities | -- | -- | -- | -- | -- | -- | -- | $0 |
| **Total Current Liabilities** | $3.68M | $3.98M | $4.06M | $2.76M | $2.79M | $2.15M | $2.40M | $3.52M |
| **Total Non-Current Liabilities** | $178K | $226K | $251K | $1.85M | $1.85M | $3.53M | $3.33M | $3.33M |
| **Total Liabilities** | $3.86M | $4.20M | $4.31M | $4.61M | $4.64M | $5.68M | $5.72M | $6.85M |
| **Total Debt (incl. Leases)** | $374K | $425K | $436K | $468K | $485K | $508K | $489K | $526K |
| Common Stock | $1.95M | $160K | $46K | $42K | $42K | $8.0K | $8.0K | $2.0K |
| Retained Earnings | -$63.98M | -$61.45M | -$57.90M | -$55.17M | -$50.75M | -$47.49M | -$44.99M | -$43.25M |
| **Total Stockholders' Equity** | $2.97M | $44K | $291K | $2.60M | $6.98M | $120K | $2.59M | -$3.99M |
| Total Equity | $2.97M | $44K | $291K | $2.60M | $6.98M | $120K | $2.59M | -$3.99M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Net Income | -$11.91M | -$16.52M | -$5.11M |
| Depreciation & Amortization | $14K | $25K | $45K |
| Stock-Based Compensation | $134K | $5.86M | $130K |
| Change in Payables | -$142K | $610K | $79K |
| **Operating Cash Flow** | -$10.82M | -$8.40M | -$4.53M |
| Capital Expenditure | -$9.0K | -$22K | -$12K |
| **Free Cash Flow** | -$10.83M | -$8.42M | -$4.54M |
| **Investing Cash Flow** | -$14K | -$22K | $573K |
| **Financing Cash Flow** | $15.64M | $5.10M | $522K |
| **Net Change in Cash** | $4.81M | -$3.31M | -$3.43M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$2.53M | -$3.55M | -$2.73M | -$4.41M | -$3.26M | -$2.50M | -$1.74M | -$1.75M |
| Depreciation & Amortization | $2.0K | $3.0K | $2.0K | $3.0K | $4.0K | $3.0K | $4.0K | -$12K |
| Stock-Based Compensation | $16K | $197K | $345K | $38K | $38K | $37K | $21K | $0 |
| Change in Payables | $64K | $268K | $125K | -$159K | $254K | -$30K | -$207K | $131K |
| **Operating Cash Flow** | -$2.11M | -$2.92M | -$3.65M | -$3.02M | -$2.84M | -$2.51M | -$2.45M | -$2.93M |
| Capital Expenditure | -$42K | $0 | $0 | -$2.0K | $0 | -$1.0K | -$6.0K | $0 |
| **Free Cash Flow** | -$2.15M | -$2.92M | -$3.65M | -$3.02M | -$2.84M | -$2.51M | -$2.46M | -$2.93M |
| **Investing Cash Flow** | -$42K | -$1.0K | $0 | -$7.0K | $0 | -$1.0K | -$6.0K | $0 |
| Common Stock Issued | $1.90M | $1.99M | $83K | -- | $0 | $0 | $0 | -- |
| **Financing Cash Flow** | $4.70M | $2.74M | $83K | -$221K | $8.62M | -$195K | $7.43M | -- |
| **Net Change in Cash** | $2.55M | -$186K | -$3.56M | -$3.24M | $5.78M | -$2.70M | $4.97M | -$742K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Return on Equity (ROE) | -457.6% | -- | -- |
| Return on Assets (ROA) | -165.1% | -577.0% | -97.2% |
| Current Ratio | 2.41x | 0.64x | 2.27x |
| Quick Ratio | 2.17x | 0.34x | 2.09x |
| Debt to Equity | 0.18x | -- | -- |
| EPS Growth (YoY) | -97.7% | -100.0% | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -445.7% | -31722.7% | -4436.4% | -457.6% | -132.5% | -14870.8% | -650.9% | -- |
| Return on Assets (ROA) | -193.8% | -328.7% | -280.5% | -165.1% | -79.6% | -307.8% | -202.6% | -577.0% |
| Current Ratio | 1.66x | 0.94x | 1.00x | 2.41x | 3.97x | 2.44x | 3.22x | 0.64x |
| Quick Ratio | 1.29x | 0.56x | 0.59x | 2.17x | 3.32x | 1.61x | 2.57x | 0.34x |
| Debt to Equity | 0.13x | 9.66x | 1.50x | 0.18x | 0.07x | 4.23x | 0.19x | -- |
| EPS Growth (YoY) | -98.0% | -88.0% | -77.9% | -- | -100.0% | -100.0% | -100.0% | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
